Download by
Scanning QR Code
No Stock Yet
No Data
Exagen's Return On Capital Employed Overview
Exagen (NASDAQ:XGN) brought in sales totaling $10.39 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 45.64%, resulting in a loss of $10.27 million. In Q4, Exa
Exagen (XGN) Stock Price: Why It Increased 10.78% Today
The stock price of Exagen Inc. (Nasdaq: XGN) increased by 10.78% today. This is why. The stock price of Exagen Inc. (Nasdaq: XGN) increased by 10.78% today. Investors are responding positively to Exa
Exagen Shares Rise 12% After Partnership With MediNcrease Health
By Chris Wack Exagen Inc. shares were up 12% to $6.73 after the company was added to MediNcrease Health Plans LLC's national provider network, providing enhanced care to their 7.5 million commercial
Exagen expands coverage for its AVISE tests with MediNcrease provider network
Exagen (NASDAQ:XGN) on Thursday said it had been added to MediNcrease Health Plans' national provider network. XGN said the addition will expand the coverage of the company's products to MediNcrease H
Exagen Highlights Addition Of Exagen MediNcrease Health Plans's Provider Network
Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans, LLC's national provider network, providing enhanc
Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth Stock Conference, which takes place June 6-9, 2022, in
Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered s
KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating
11:06 AM EDT, 05/13/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Exagen Price Target Cut to $17.00/Share From $20.00 by Keybanc
Exagen Price Target Cut to $17.00/Share From $20.00 by Keybanc
Exagen Is Maintained at Overweight by Keybanc
Exagen Is Maintained at Overweight by Keybanc
Loading...
No Stock Yet